Real-World Patient Characteristics, Burden, and Quality of Life in C3 Glomerulopathy and Primary Immune Complex Membranoproliferative Glomerulonephritis
Kidney360 · 2025
DOI: 10.34067/kid.0000001059 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Kidney360, 2025. Verfasst von Fernando Caravaca-Fontan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain. Hauptthemen laut MEDLINE: Quality of Life, Glomerulonephritis, Membranoproliferative, Cost of Illness, Complement C3. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
C3 glomerulopathy (C3G) and primary immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) are rare, progressive kidney disorders affecting both children and adults. This real-world study aimed to assess the clinical, economic, and humanistic burden of these conditions in Europe and the United States of America, addressing key evidence gaps.
Methods
A large, multinational, cross-sectional survey gathered data from treating healthcare professionals (HCPs) and patients during routine clinical care. Both groups completed surveys reflecting their experiences with C3G or primary IC-MPGN.
Results
In C3G 93 physicians returned data for 289 patients, and 52 patients completed a survey themselves, and for primary IC-MPGN 61 physicians returned data for 215 patients, and 54 patients completed a survey themselves. Baseline clinical characteristics and comorbidity rates were similar across both groups. At the time of survey, 81% (C3G) and 89% (primary IC-MPGN) of patients had stable or improving disease. Average 24-hour proteinuria levels were 2.3 g/24h (C3G) and 1.6 g/24h (IC-MPGN). Proteinuria was the most commonly reported symptom by physicians (69% and 56%), while fatigue or low energy was most frequently reported by patients (50% and 53%). Overall, patient-reported FACIT-Fatigue score was 34.7 (C3G) and 34.9 (primary IC-MPGN), on a scale of 0–52 where a higher score indicates better quality of life. On average, patients saw a physician 12.3 (C3G) and 10.7 (IC-MPGN) times in the past year, relating to their C3G/ IC-MPGN. Among adults, 42% (C3G) and 31% (IC-MPGN) were not employed full-time. Caregiver support was reported in 15% (C3G) and 25% (IC-MPGN) of cases.
Conclusions
Despite slowly progressing disease in the current cohort, C3G and primary IC-MPGN create a significant clinical, economic and healthcare burden among affected patients and their families.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain.
- Loma Linda University Medical Center, Loma Linda, California.
- Apellis Pharmaceuticals, Waltham, Massachusetts.
- Adelphi Real World, Bollington, United Kingdom.
- Swedish Orphan Biovitrum, Stockholm, Sweden.
ORCID-Profile: Fernando Caravaca-Fontan, Sayna Norouzi, Mingyi Huang, Kathryn Gordon, Sarah Clayton, Mollie Lowe, Chloe Middleton-Dalby, Lucia Quintana-Gallardo, Carly Rich
Zitieren
APA
Caravaca-Fontan, F., Norouzi, S., Huang, M., Gordon, K., Clayton, S., Lowe, M., Fitzmaurice, K., Middleton-Dalby, C., Quintana-Gallardo, L., & Rich, C. (2025). Real-World Patient Characteristics, Burden, and Quality of Life in C3 Glomerulopathy and Primary Immune Complex Membranoproliferative Glomerulonephritis. Kidney360. https://doi.org/10.34067/kid.0000001059
Vancouver
Caravaca-Fontan F, Norouzi S, Huang M, Gordon K, Clayton S, Lowe M, et al. Real-World Patient Characteristics, Burden, and Quality of Life in C3 Glomerulopathy and Primary Immune Complex Membranoproliferative Glomerulonephritis. Kidney360. 2025. doi:10.34067/kid.0000001059
BibTeX
@article{CaravacaFontan2025,
author = {Caravaca-Fontan, Fernando and Norouzi, Sayna and Huang, Mingyi and Gordon, Kathryn and Clayton, Sarah and Lowe, Mollie and Fitzmaurice, Kristie and Middleton-Dalby, Chloe and Quintana-Gallardo, Lucia and Rich, Carly},
title = {Real-World Patient Characteristics, Burden, and Quality of Life in C3 Glomerulopathy and Primary Immune Complex Membranoproliferative Glomerulonephritis},
journal = {Kidney360},
year = {2025},
doi = {10.34067/kid.0000001059}
}
EUVIMED